8-KLeadership ChangesOther Events

Guardant Health, Inc. 8-K Report, Executive Changes (Feb 28, 2022)

Filed February 28, 2022For Securities:GH

Summary

Guardant Health, Inc. (GH) filed an 8-K on February 28, 2022, primarily detailing changes to its Board of Directors and corporate governance practices. A key event is the departure of director Stanley Meresman, who will not seek re-election at the upcoming June 2022 Annual Meeting of Stockholders. This departure is stated to be amicable and not due to any disputes. The filing also highlights significant enhancements to the Company's corporate governance structure, undertaken in response to stockholder feedback and aiming to strengthen oversight and accountability. These governance enhancements include expanding the Board's size, increasing female representation, and amending the charters of key committees, particularly the Nominating and Corporate Governance Committee. The Company has also updated its Code of Conduct to provide more specific guidance on ethical behavior and conflicts of interest. Furthermore, Guardant Health plans to enhance disclosures in its upcoming 10-K regarding human capital management and DEI initiatives. These changes signal a proactive approach by the Board to improve its governance framework in line with evolving stakeholder expectations.

Key Highlights

  • 1Director Stanley Meresman will not stand for re-election at the June 2022 Annual Meeting of Stockholders.
  • 2Mr. Meresman's decision to depart is not related to any dispute with the Company, its management, or the Board.
  • 3Guardant Health has increased its Board size from seven to nine directors.
  • 4The Company has increased female representation on the Board, now comprising four female directors.
  • 5The charter of the Nominating and Corporate Governance Committee has been amended to enhance oversight of CSR, ESG, ethical compliance, and IT initiatives.
  • 6The Code of Conduct has been updated with expanded and refined standards for directors, officers, and employees, including areas like conflicts of interest and antitrust practices.
  • 7Board committee memberships have been refreshed, limiting committee chair service to one committee and providing new directors with committee experience.

Frequently Asked Questions

Stanley Meresman has informed the Company that he will not stand for re-election at the upcoming Annual Meeting of Stockholders in June 2022. He has stated that his decision is not a result of any dispute or disagreement with the Company, its management, or the Board.

Guardant Health has made several enhancements to its corporate governance in response to stockholder feedback. These include increasing the Board size, boosting female representation, amending the Nominating and Corporate Governance Committee charter to broaden its oversight (including ESG and ethical compliance), and updating the Code of Conduct with more specific ethical guidelines. The Company also plans to expand disclosures on human capital management and DEI in its 10-K filing and has refreshed Board committee memberships.

Yes, the filing explicitly mentions increasing female representation on the Board, which now consists of four female directors. Additionally, the Company plans to expand disclosure in its Annual Report on Form 10-K addressing its human capital management and its diversity, equality, and inclusion initiatives.

Effective May 1, 2022, the Audit Committee will be chaired by Stanley Meresman and include Meghan Joyce and Myrtle Potter. The Compensation Committee will be chaired by Vijaya Gadde and include Samir Kaul and Ms. Potter. The Nominating and Corporate Governance Committee will be chaired by Ian Clark and include Bahija Jallal and Ms. Joyce. The Board will appoint a replacement for Mr. Meresman on the Audit Committee before his term concludes.